Cargando…
Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab
BACKGROUND: Vaccination has proven to be effective in preventing SARS-CoV-2 transmission and severe disease courses. However, immunocompromised patients have not been included in clinical trials and real-world clinical data point to an attenuated immune response to SARS-CoV-2 vaccines among patients...
Autores principales: | Räuber, Saskia, Korsen, Melanie, Huntemann, Niklas, Rolfes, Leoni, Müntefering, Thomas, Dobelmann, Vera, Hermann, Alexander M, Kölsche, Tristan, von Wnuck Lipinski, Karin, Schroeter, Christina B, Nelke, Christopher, Regner-Nelke, Liesa, Ingwersen, Jens, Pawlitzki, Marc, Teegen, Bianca, Barnett, Michael Harry, Hartung, Hans-Peter, Aktas, Orhan, Albrecht, Philipp, Levkau, Bodo, Melzer, Nico, Ruck, Tobias, Meuth, Sven G, Kremer, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889453/ https://www.ncbi.nlm.nih.gov/pubmed/35193952 http://dx.doi.org/10.1136/jnnp-2021-328197 |
Ejemplares similares
-
Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab
por: Räuber, Saskia, et al.
Publicado: (2022) -
Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021) -
Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials
por: Giovannoni, Gavin, et al.
Publicado: (2021) -
Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses
por: Novak, Frederik, et al.
Publicado: (2023) -
Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial
por: Vermersch, Patrick, et al.
Publicado: (2021)